Skip to main content
SpringerLink
Log in

Introduction Neuropharmacology of Movement Disorders

Comparison of Spontaneous and Drug-Induced Movement Disorders

  • Chapter
Movement Disorders

Abstract

Disorders of voluntary movement are common neurological problems that have unusual importance to both clinician and scientist. Movement disorders are important to the clinician because they are generally among the most treatable neuropsychiatric disorders, yet are also among the most frequent iatrogenic complications of drug therapies. Thus, the clinician is in a powerful position both to create and to alleviate movement disorders. Proper understanding of these conditions will help the clinician distinguish spontaneously occurring diseases from the ones he creates with drugs. Proper understanding of neuro-pharmacology will help the clinician to use drug treatments to alleviate movement disorders while avoiding or reducing complications from improper drug usage. For the neuroscientist, movement disorders represent simultaneously the greatest triumphs as well as the greatest failures of basic brain research. The triumphs include the first breakthroughs in applications of neurotransmitter mechanisms to neuronal functioning. Knowledge of basal ganglia anatomy, biochemistry, and pharmacology has led, for example, to the development of treatments for Parkinson’s disease. On the other hand, the failures include the production of unwanted movement disorders by numerous drugs, including the irreversible and disabling disease tardive dyskinesia. Understanding these lessons, both good and bad, from the field of movement disorders puts the basic scientist in a strong position to develop future treatments for other disorders of the human central nervous system.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Adams, R. D., and Victor, M., 1981, Principles of Neurology, McGraw-Hill, New York.

    Google Scholar 

  • Ayd, F. J., 1961, A survey of drug induced extrapyramidal reactions, J.A.M.A. 175:1054–1060.

    Google Scholar 

  • Baldessarini, R. J., and Tarsy, D., 1978, Tardive dyskinesia, in: Psychopharmacology: A Generation of Progress ( M. A. Lipton, A. Dimascio, and K. R. Killam, eds.), pp. 993–1004, Raven Press, New York.

    Google Scholar 

  • Barbeau, A., Chase, T. N., and Paulson, G. W. (eds.), 1973, Huntington’s Chorea, 1872–1972, Advances in Neurology Series, Vol. 1, Raven Press, New York.

    Google Scholar 

  • Barbeau, A., Growdon, J. H., and Wurtman, R. J. (eds.), 1979, Nutrition and the Brain, Volume 5, Choline and Lecithin in Brain Disorders, Raven Press, New York.

    Google Scholar 

  • Barchas, J. D., Berger, P. A., Ciaranello, R. D., and Elliott, G. R. (eds.), 1977, Psychopharmacology: From Theory to Practice, Oxford University Press, New York.

    Google Scholar 

  • Barnes, T. R. E., and Braude, W. M., 1985, Akathisia variants and tardive dyskinesia, Arch. Gen. Psychiatry, 42: 874–878.

    Article  PubMed  CAS  Google Scholar 

  • Berger, P. A., and Rexroth, K., 1980, Tardive dyskinesia: Clinical, biological and pharmacological perspectives, Schizophr., Bull. 6: 102–116.

    CAS  Google Scholar 

  • Bing, R., 1923, Ueber einige bemerkenswerte begleitersche inungen der “extrapyramidalen rigiditat (akathisie-mikrographie-kinesia paradoxa), Schweiz. Med. Wochenschr. 4: 167–171.

    Google Scholar 

  • Bing, R., 1939, Textbook of Nervous Diseases, 5th ed., Haymaker, W. (translation and enlarged), pp. 169, 758–759, Henry Limpton Press, London.

    Google Scholar 

  • Bird, E. D., 1980, Chemical pathology of Huntington’s Disease, Ann. Rev. Pharmacol. Toxicol. 20: 533–551.

    Article  CAS  Google Scholar 

  • Bonduellle, M., and Degos, C., 1976, Symptomatic narcolepsies: A critical study, in: Narcolepsy ( C. Guilleminault, W. C. Dement, P. Passauant, eds.), pp. 313–332, Spectrum Publications, Inc., New York.

    Google Scholar 

  • Braude, W. M., Barnes, T. R. E., and Gore, S. M., 1983, Clinical characteristics of akathisia: A systematic investigation of acute psychiatric inpatient admissions. Br. J. Psychiatry 143: 139150.

    Google Scholar 

  • Caine, D. B., Chase, T. N., and Barbeau, A. (eds), 1975, Dopaminergic Mechanisms, Advances in Neurology Series, Vol. 9, Raven Press, New York.

    Google Scholar 

  • Caine, D. M., (ed.), 1973, Progress in the Treatment of Parkinsonism, Advances in Neurology Series, Vol. 3. Raven Press, New York.

    Google Scholar 

  • Casey, D. E., 1980, Pharmacology of blepharospasm-oromandibular dystonia syndrome, Neurology 30: 690–695.

    PubMed  CAS  Google Scholar 

  • Casey, D. E., Gerlach, J., Magelund, G., and Christensen, T. R., 1980, Gamma-acetylenic GABA in tardive dyskinesia. Arch. Gen. Psychiatry 37: 1376–1379.

    Article  PubMed  CAS  Google Scholar 

  • Chadwick, D., Hallett, M., Harris, R., Jenner, P., Reynolds, E. H., and Marsden, C. D., 1977, Clinical, biochemical and physiological features distinguishing myoclonus responsive to 5hydroxytryptophan, tryptophan with a monoamine oxidase inhibitor, and clonazepam, Brain 100: 455–487.

    Article  PubMed  CAS  Google Scholar 

  • Chase, T. N., Wexler, N. S., Barbeau, A. (eds.), 1979, Huntington’s Disease, Advances in Neurology Series, Vol. 23, Raven Press, New York.

    Google Scholar 

  • Cohen, D. J., Young, J. G., Nathanson, J. A., and Shaywitz, B. A., 1979, Clonidine in Tourette’s syndrome, Lancet 2: 551–553.

    Article  PubMed  CAS  Google Scholar 

  • Cohen, D. J., Detlor, J., Young, J. G., and Shaywitz, B. A., 1980, Clonidine ameliorates Gilles de la Tourette syndrome, Arch. Gen. Psychiatry 37: 1350–1357.

    Article  PubMed  CAS  Google Scholar 

  • Critchley, E., 1949, Observations on essential (heredofamilial) tremor, Brain 72:113–139. Critchley, E., 1972, Clinical manifestations of essential tremor, J. Neurol. Neurosurg. Psychiatry 35: 365–372.

    Article  Google Scholar 

  • Davidson, A. B., Bofe, E., MacNeil, D. A., and Cock, L., 1983, Pharmacologic effects of R0221319: A new antipsychotic agent, Psychopharmacology 79: 32–39.

    Article  PubMed  CAS  Google Scholar 

  • Davis, K. L., and Berger, P. A., 1978, Pharmacological investigations of the cholinergic imbalance hypotheses of movement disorders and psychosis, Biol. Psychiatry 13: 23–49.

    PubMed  CAS  Google Scholar 

  • Davis, K.L., and Berger, P.A. (eds.), 1979, Brain Acetylcholine and Neuropsychiatric Disease, Plenum Press, New York.

    Google Scholar 

  • Davis, K. L., Hollister, L. E., Berger, P. A., and Barchas, J. D., 1975, Cholinergic imbalance hypotheses of psychoses and movement disorders: Strategies for evaluation, Psychopharmacol. Commun. 1: 533–543.

    PubMed  CAS  Google Scholar 

  • Davis, K. L., Hollister, L. E., Barchas, J. D., and Berger, P. A., 1976, Choline in tardive dyskinesia and Huntington’s disease, Life Sci. 19: 1507–1516.

    Article  PubMed  CAS  Google Scholar 

  • DeVeaugh-Geiss, J., 1980, Tardive Tourette syndrome, Neurology 30: 562–563.

    PubMed  CAS  Google Scholar 

  • DeVeaugh-Geiss, J. (ed.), 1982, Tardive Dyskinesia and Related Involuntary Movement Disorders, John Wright, Boston.

    Google Scholar 

  • Ekbom, K. W., 1944, Asthensia Crurum parathestica (irritable legs), Acta Med. Scand. 118: 197.

    Article  Google Scholar 

  • Ekbom, K. A., 1960, Restless legs syndrome, Neurology 10: 868–873.

    PubMed  CAS  Google Scholar 

  • Eldridge, R., and Fahn, S. (eds.), 1976, Dystonia, Advances in Neurology Series, Vol. 14, Raven Press, New York.

    Google Scholar 

  • Fahn, S., 1979, Treatment of dystonia with high-dosage anticholinergic medication, Neurology 29: 605.

    Google Scholar 

  • Fann, W. E., Lake, C. R., Gerber, C. J., and McKenzie, G. M., 1974, Cholinergic suppression of tardive dyskinesia, Psychopharmacology 37: 101–107.

    Article  CAS  Google Scholar 

  • Fann, W. E., Smith, R. C., Davis, J. M., and Domino, E. F. (eds.), 1980, Tardive Dyskinesia, SP Medical and Scientific Books, New York.

    Google Scholar 

  • Fog, R., and Pakkenberg, H., 1980, Theoretical and clinical aspects of the Tourette Syndrome (chronic multiple tics), J. Neural. Transm. 16 (Suppl): 211–215.

    Google Scholar 

  • Foster, N. L., Chase, T. N., Denaro, A., Hare, T. A., and Tamminga, C. A., 1983, THIP treatment of Huntington disease, Neurology 33: 637–639.

    PubMed  CAS  Google Scholar 

  • Freedman, D. X., and DeJong, J., 1961a, Thresholds for drug-induced akathisia, Am. J. Psychiatry 117: 930–931.

    PubMed  CAS  Google Scholar 

  • Freedman, D. X. and DeJong, J., 1961b, Factors that determine drug-induced akathisia, Dis. Nerv. Sys. 22: 2–8.

    Google Scholar 

  • Friedhoff, A., and Chase, T. N. (eds.), 1982, Tourette Syndrome, Advances in Neurology Series, Raven Press, New York.

    Google Scholar 

  • Gardos, G., Cole, J. O., and Tarsy, D., 1978, Withdrawal syndromes associated with antipsychotic drugs Am. J. Psychiatry 135: 1321–1324.

    PubMed  CAS  Google Scholar 

  • Gelenberg, A. J., Doller-Wojcik, J. C., and Growdon, J. H., 1979, Choline and lecithin in the treatment of tardive dyskinesia: preliminary results from a pilot study. Am. J. Psychiatry 36: 772–776.

    Google Scholar 

  • Gerlach, J., Reisby, N., and Randrup, A., 1974, Dopaminergic hypersensitivity and cholinergic hypofunction in the pathophysiology of tardive dyskinesia, Psychopharmacology 34: 21–25.

    Article  CAS  Google Scholar 

  • Gold, M. S., Redmond, D. E., and Kleber, H. D., 1978, Clonidine blocks acute opiate-withdrawal symptoms, Lancet 2: 599–602.

    Article  PubMed  CAS  Google Scholar 

  • Gold, M. S., Pottash, A. C., Annitto, W. J., Extein, I., and Kleber, H. D., 1981, Lofexidine, a clonidine analogue effective in opiate withdrawal, Lancet 1: 992–993.

    Google Scholar 

  • Gold, M. S., Pottash, A. C., and Extein, I., 1982, Clonidine: inpatient studies from 1978 to 1981, J. Clin. Psychiatry 43(6)(sec. 2 ): 35–38.

    Google Scholar 

  • Goodman, L. S., and Gilman, A. (eds.), 1982, The Pharmacological Basis of Therapeutics, Macmillan, New York.

    Google Scholar 

  • Groves, P. M., 1983, A theory of the functional organization of the neostriatum and the neostriatal control of voluntary movement, Brain Res. Rev. 5: 198–132.

    Article  Google Scholar 

  • Growdon, J. H., and Wurtman, R. J., 1979, Oral choline administration to patients with Hunting-ton’s Disease, in: Huntington’s Disease. Advances in Neurology Series, Vol. 23 ( T. N. Chase, N. S. Wexler, and A. Barbeau, eds.), pp. 765–776, Raven Press, New York.

    Google Scholar 

  • Halaris, A. E., 1983, The use of lithium in psychiatric practice, Psychiatry Ann. 12: 53–64.

    Google Scholar 

  • Haskovec, L., 1904, Weitere bemerkungen ueber die akathisie, Wien. Med. Wochenschr. 54: 526–530.

    Google Scholar 

  • Heikkila, R. E., Hess, A., and Duvoisin, R. C., 1984, Dopaminergic neurotoxicity of 1-methyl-4phenyl-1,2,5,6-tetrahydropyridine in mice, Science 224: 1451–1453.

    Article  PubMed  CAS  Google Scholar 

  • Hollister, L. E., 1978, Tricyclic antidepressants. N. Engl. J. Med. 299: 1168–1172.

    Article  PubMed  CAS  Google Scholar 

  • Howard, F. M., 1963, A new and effective drug in the treatment of the stiff-man syndrome: preliminary report, Mayo Clin. Proc. 38: 203–212.

    Google Scholar 

  • Iversen, L. L., 1975, Dopamine receptors in the brain, Science 188: 1084–1089.

    Article  PubMed  CAS  Google Scholar 

  • Iversen, L. L., 1983, Neuropeptides—What next? Trends Neurosci. 6: 293–294.

    Article  Google Scholar 

  • Jacquet, Y. F., and Abrams, G. M., 1982, Postural asymmetry and movement disorder after unilateral microinjection of adrenocorticotropin I-24 in rat brainstem, Science 218: 175–177.

    Article  PubMed  CAS  Google Scholar 

  • Jeste, D. V., Potkin, S. G., Sinha, S., Feder, S., and Wyatt, R. J., 1979, Tardive dyskinesiareversible and persistent, Arch. Gen. Psychiatry 36: 585–590.

    Article  PubMed  CAS  Google Scholar 

  • Kebabian, J. W., and Caine, D. B., 1979, Multiple receptors for dopamine, Nature 277: 93–96.

    Article  PubMed  CAS  Google Scholar 

  • Kendler, K. S., 1976, A medical student’s experience with akathisia, Am. J. Psychiatry, 133: 4.

    Google Scholar 

  • Keretesy, A., 1967, Paroxysmal kinesigenic choreoathetosis, Neurology 17: 680–684.

    Google Scholar 

  • Kirk, L., Baastrup, P. C., and Schou, M., 1972, Propranolol and lithium-induced tremor, Lancet 1: 839.

    Article  PubMed  CAS  Google Scholar 

  • Klawans, H. L., 1973, The Pharmacology of Extrapyramidal Movement Disorders, Karger, Basel. Klawans, H. L., and Rubovits, R., 1972, Central cholinergic-anticholinergic antagonism in Huntington’s chorea, Neurology 22: 107–112.

    Google Scholar 

  • Klawans, H. L., and Rubovits, R., 1974, Effect of cholinergic and anticholinergic agents on tardive dyskinesia, J. Neurol. Neurosurg. Psychiatry 27: 941–947.

    Article  Google Scholar 

  • Klawans, H. L., Falk, D. K., Nausieda, P. A., and Wiener, W. J., 1978, Gilles de la Tourette syndrome after long-term chlorpromazine therapy, Neurology 28: 1064–1066.

    PubMed  CAS  Google Scholar 

  • Korczyn, A. D., 1978, The pathophysiology of dystonia, J. Neural. Transm. 42: 245–250.

    Article  PubMed  CAS  Google Scholar 

  • Langston, J. W., Ballard, P., Tetrud, J. W., and Irwin, I., 1983, Chronic parkinsonism in humans due to a product of meperidine-analog synthesis, Science 219: 979–980.

    Article  PubMed  CAS  Google Scholar 

  • Langston, J. W., Irwin, I., Langston, E. B., and Forno, L. S., 1984, Pargyline prevents MPTPinduced Parkinsonism in primates, Science 255: 1480–1482.

    Article  Google Scholar 

  • Lewin, R., 1984a, Trail of ironies to Parkinson’s disease: Sloppy chemical synthesis by an illicit drug producer has led to important insights into the basic cause of Parkinson’s disease, Science 224: 1083–1085.

    Article  PubMed  CAS  Google Scholar 

  • Lewin, R., 1984b, Brain enzyme is the target of drug toxin: A chemical known as MPTP causes a Parkinson-like state in humans and monkeys; biochemical and autoradiographical studies are closing in on the mechanism, Science 225: 1460–1462.

    Article  PubMed  CAS  Google Scholar 

  • Lewis, B. V., and Parsons, M., 1966, Chorea gravidarum, Lancet 1: 284.

    Article  PubMed  CAS  Google Scholar 

  • LeWitt, P. A., Newman, R. P., Miller, L. P., Lovenberg, W., and Eldridge, R., 1983, Treatment of dystonia with tetrahydrobiopterin, N. Engl. J. Med. 308: 157–158.

    PubMed  CAS  Google Scholar 

  • Luchins, D. J., Freed, W. J., and Wyatt, R. J., 1980, The role of cholinergic supersensitivity in the medical symptoms associated with withdrawal of antipsychotic drugs, Am. J. Psychiatry 137: 1395–1398.

    PubMed  CAS  Google Scholar 

  • Lundberg, J. M., and Hokfelt, T., 1983, Coexistence of peptides and classical neurotransmitters, Trends Neurosci. 6: 325–333.

    Article  CAS  Google Scholar 

  • Magnussen, I., Dupont, E., Engback, F., and de Fine Olivarius, B., 1978, Posthypoxic intention myoclgnus treated with 5-hydroxytryptophan and an extracerebral decarboxylase inhibitor, Acta Neurolog. Scand. 57: 289–294.

    Article  CAS  Google Scholar 

  • Marsden, C. D., 1976, Blepharospasm-oromandibular dystonia syndrome (Brueghel’s syndrome), J. Neurol. Neurosurg. Psychiatry 39: 1204–1209.

    Article  PubMed  CAS  Google Scholar 

  • Marsden, C. D., 1982, Basal ganglia disease, Lancet 2: 21–27.

    Google Scholar 

  • Marsden, C. D., Tarsy, D., and Baldessarini, R. J., 1975, Spontaneous and drug-induced movement disorders in psychotic patients, in: Psychiatric Aspects of Neurological Disease ( D. F. Benson and D. Blumer, eds.), pp. 219–265, Grune and Stratton, New York.

    Google Scholar 

  • Martin, G. E., Williams, M., Pettibone, D. J., Yarbrough, G. G., Clineschmidt, B. V., and Jones, J. H., 1984, Pharmacologic profile of a novel potent direct-acting dopamine agonist, propyl-9-hydroxynaphthoxazine (+-PHNO), J. Pharmacol. Exp. Ther. 229: 569–576.

    Google Scholar 

  • Martin, J. B., 1984, Huntington’s disease: New approaches to an old problem, Neurology 34: 1059–1072.

    PubMed  CAS  Google Scholar 

  • McDowell, F., and Barbeau, A. (eds.), 1974, Second Canadian-American Conference on Parkinson’s Disease, Advances in Neurology Series, Vol. 5, Raven Press, New York.

    Google Scholar 

  • Meltzer, H. Y., and Stahl, S. M., 1976, The dopamine hypothesis of schizophrenia: A review, Schizophr. Bull. 2: 19–76.

    PubMed  CAS  Google Scholar 

  • Moersch, F. P., and Woltman, H. W., 1956, Progressive fluctuating rigidity and spasm (“stiff-man” syndrome): Report of a case and some observations in 13 other cases, Mayo Clin. Proc. 31: 421–427.

    CAS  Google Scholar 

  • Moore, D. C., and Bowers, M. B., 1980, Identification of a subgroup of tardive dyskinesia patients by pharmacologic probes, Am. J. Psychiatry 137: 1202–1205.

    Google Scholar 

  • Nakajima, T., Kurlima, I., Nakamura, K., and Davidson, A. B., 1983, Interaction of pyrroloisoquinoline antipsychotics with a D-2 dopamine receptor subtype evaluation by 3H-R022–1319 binding, Soc. Neurosci. 9: 431.

    Google Scholar 

  • Newman, R. P., LeWitt, P. A., Raphaelson, M. I., Foster, N. L., Calne, D. B., and Chase, T. N., 1982, Dystonia: Therapy with dopaminergic ergot derivatives, Ann. Neurol. 12: 82.

    Google Scholar 

  • Nutt, J. G., Woodward, W. R., Hammerstad, J. P., Carter, J. H., and Anderson, J. L., 1984, the “on-off’ phenomenon in Parkinson’s disease: Relation to levodopa absorption and transport, N. Engl. J. Med. 310: 483–488.

    Google Scholar 

  • O’Flanagan, P. M., 1975, Clonazepam in the treatment of drug-induced dyskinesia, Br. Med. J. 1: 269–270.

    Article  PubMed  Google Scholar 

  • Olafson, R. A., Mulden, D. W., and Howard, F. M., 1964, Stiff-man syndrome: A review of the literature, report of three additional cases and discussion of pathophysiology and treatment, Mayo Clin. Proc. 39: 131–143.

    PubMed  CAS  Google Scholar 

  • Olsen, G. L., Cheung, H. C., Morgan, M. D., Blount, J. F., Todaro, L., Berger, L., Davidson, A. B., and Boff, E., 1981, A dopamine model and its application in the design of a new class of rigid pyrrolo[2,3.g] isoquinoline antipsychotics, J. Med. Chem. 24: 1026–1034.

    Article  Google Scholar 

  • Paulson, G. W., 1973, Meige’s Syndrome, Geriatrics 27: 69–73.

    Google Scholar 

  • Paulson, G. W., Shaw, G., and Malarkey, W. B., 1979, Huntington’s Disease, INH and prolactin levels, Adv. Neurol. 23: 797–801.

    Google Scholar 

  • Perry, T. L., Wright, J. M., Hansen, S., and McLeod, P. M., 1979, Isoniazid therapy of Huntington’s disease, Adv. Neurol. 23: 785–796.

    Google Scholar 

  • Quinn, N., Parkes, J. D., and Marsden, C. D., 1984, Control of on/off phenomenon by continuous intravenous infusion of levodopa, Neurology 34: 1131–1136.

    PubMed  CAS  Google Scholar 

  • Ricker, R., and Mertens, H. G., 1968, EMG phenomena in the stiff-man syndrome, Electroencephalogr. Clin. Neurosphysiol. 25: 413.

    Google Scholar 

  • Roberts, E., Chase, T. N., Tower, D. B. (eds.), 1976, GABA in Nervous System Function, Raven Press, New York.

    Google Scholar 

  • Rubovits, R., and Klawans, H. L., 1972, Implications of amphetamine-induced stereotyped behavior as a model for tardive dyskinesia, Arch. Gen. Psychiatry 27: 502–507.

    Article  PubMed  CAS  Google Scholar 

  • Schmidt, R. T., Stahl, S. M., and Spehlmann, R., 1975, A pharmacologic study of the stiff-man syndrome: Correlation of clinical symptoms with urinary 3-methoxy-4-hydroxy-phenyl glycol (MHPG) excretion, Neurology 35: 622–626.

    Google Scholar 

  • Sedman, G., 1976, Clonazepam in the treatment of tardive oral dyskinesia, Br. Med. J. 2: 583.

    Article  PubMed  CAS  Google Scholar 

  • Shoulson, I., Chase, T. N., Roberts, E., and van Balgooy, J. N., 1975, Huntington’s disease: Treatment with imidazole-4-acetic acid, N. Engl. J. Med. 293: 504–505.

    PubMed  CAS  Google Scholar 

  • Shoulson, I., Kartzinel, R., and Chase, T. N., 1976, Huntington’s disease: Treatment with dipropylacetic acid and gamma-aminobutyric acid, Neurology 26: 61–63.

    PubMed  CAS  Google Scholar 

  • Sovner, R., and Dimascio, A., 1977, The effect of benztropine mesylate in the rabbit syndrome and tardive dyskinesia, Am. J. Psychiatry 134: 1301–1302.

    PubMed  CAS  Google Scholar 

  • Spehlmann, R., and Stahl, S. M., 1976, Dopamine-acetylcholine imbalance in Parkinson’s disease: Possible regenerative overgrowth of cholinergic axon terminals, Lancet 1: 724–726.

    Article  PubMed  CAS  Google Scholar 

  • Stahl, S. M., 1980, Tardive Tourette Syndrome in an autistic patient after long-term neuroleptic administration, Am. J. Psychiatry 137: 1267–1269.

    PubMed  CAS  Google Scholar 

  • Stahl, S. M., 1984, Constant drug delivery of dopamine agonists and antagonists: Possible prevention or treatment of tardive dyskinesia and levodopa dyskinesia. Abstracts of the American College of Neuropsychopharmacology Meeting, American College of Neuropsychopharmacy Press, Vanderbilt, Tennessee.

    Google Scholar 

  • Stahl, S. M., 1985, Akathisia and tardive dyskinesia: Changing concepts, Arch. Gen. Psychiatry 42: 915–917.

    Article  PubMed  CAS  Google Scholar 

  • Stahl, S. M., and Berger, P. A., 1981a, Physostigmine in Tourette Syndrome: evidence for cholinergie underactivity, Am. J. Psychiatry 138: 240–242.

    Article  PubMed  CAS  Google Scholar 

  • Stahl, S. M., and Berger, P. A., 198 lb, Bromocriptine in dystonia, Lancet 2: 745.

    Google Scholar 

  • Stahl, S. M., and Berger, P.A., 1982a, Cholinergic and dopaminergic mechanisms in Tourette syndrome, in: Tourette Syndrome. Advances in Neurology Series, Vol. 35 ( T. N. Chase and A. J. Friedhoff, eds.), pp. 141–150, Raven Press, New York.

    Google Scholar 

  • Stahl, S. M., and Berger, P. A., 1982b, Neuroleptic effects in Tourette syndrome predict dopamine excess and acetylcholine deficiency, Biol. Psychiatry 17: 1047–1053.

    PubMed  CAS  Google Scholar 

  • Stahl, S. M., and Berger, P. A., 1982c, Bromocriptine, physostigmine and neurotransmitter mechanisms in the dystonias, Neurology 32: 889–892.

    PubMed  CAS  Google Scholar 

  • Stahl, S. M., Layzer, R. B., Aminoff, M. J., Townsend, J. J., and Feldon, S., 1980, Continuous cataplexy in a patient with a midbrain tumor: The limp man syndrome, Neurology 30: 1115–1118.

    PubMed  CAS  Google Scholar 

  • Stahl, S. M., Davis, K. L., and Berger, P. A., 1982a, Neuropharmacology of tardive dyskinesia, spontaneous dyskinesia and other dystonias, J. Clin. Psychopharmacol. 2: 32 1328.

    Google Scholar 

  • Stahl, S. M., Yesavage, J. A., and Berger, P. A., 1982b, Pharmacologic characteristics of idiopathic orofacial dyskinesia (Meige dystonia): Differentiation from tardive dyskinesia, J. Clin. Psychiatry 43: 445–446.

    PubMed  CAS  Google Scholar 

  • Stahl, S. M., Berger, P. A., Newman, R. P., and LeWitt, P., 1984, Bromocriptine and lisuride in dystonias, Neurology 34: 135–136.

    Google Scholar 

  • Stahl, S. M., Thornton, J. E., Simpson, M. L., Berger, P. A., and Napoliello, M., 1985a, Gammavinyl-GABA in tardive dyskinesia and other movement disorders, Biol. Psychiatry 20: 888–893.

    Article  PubMed  CAS  Google Scholar 

  • Stahl, S. M., Faull, K. F., Barchas, J. D., and Berger, P. A., 1985b, Cerebrospinal fluid monoamine metabolites in movement disorders and normal aging, Arch. Neurol. 42: 166–169.

    Article  PubMed  CAS  Google Scholar 

  • Stahl, S. M., Thiemann, S., Faull, K. F., Barchas, J. D., and Berger, P. A., 1985c, Neurochemistry of dopamine in Huntington Dementia and normal aging, Arch. Gen. Psychiatry,in press.

    Google Scholar 

  • Stahl, S. M., Thornton, J. E., and Berger, P. A., 1985d, Gamma-aminobutyric acid and movement disorders: Role of gamma-vinyl-GABA, in: Clinical and Pharmacological Studies in Psychiatric Disorders (G. D. Burrows and T. R. Norman, eds.), John Libby, London, in press.

    Google Scholar 

  • Steck, H., 1954, Le syndrome extrapyramidal et diencephalique au cours des traitments au largactil et au serpasil, Ann. Med-Psych. 112: 737–743.

    CAS  Google Scholar 

  • Sweet, R. D., Blumberg, J., Lee, J. M., and McDowell, F. H., 1974, Propranolol treatment of essential tremor, Neurology 24: 64–67.

    PubMed  CAS  Google Scholar 

  • Tamminga, C. A., Crayton, J. W., and Chase, T. N., 1979, Improvement in tardive dyskinesia after muscimol therapy, Arch. Gen. Psychiatry 36: 595–598.

    Article  PubMed  CAS  Google Scholar 

  • Tamminga, C. A., Smith, R. C., and Davis, J. M., 1980, The effects of cholinergic drugs on the involuntary movements of tardive dyskinesia, in: Tardive Dyskinesia ( W. E. Fann, R. C. Smith, J. M. Davis and E. E. Domino, eds.), pp. 411–418, SP Medical and Scientific Books, New York.

    Chapter  Google Scholar 

  • Tamminga, C. A., Thaker, G. K., Ferraro, T. N., and Hare, T. A., 1983, GABA agonist treatment improves tardive dyskinesia, Lancet 11: 97–98.

    Article  Google Scholar 

  • Tanner, C. M., Goetz, C. G., Weiner, W. J., Nausieda, P. A., Wilson, R., and Klawans, H. L., 1979, The role of cholinergic mechanisms in spasmodic torticollis, Neurology 29: 604–605.

    Google Scholar 

  • Tanner, C. M., Goetz, C. G., Glantz, R. H., Nausieda, P. A., Weiner, W. J., and Klawans, H. L., 1981, Cholinergic mechanisms in idiopathic partial and segmented dystonias, Ann. Neurol. 10: 94.

    Google Scholar 

  • Tarsy, D., 1976, Dopamine-acetylcholine interaction in the basal ganglia, in: Basic and Clinical Aspects of Neurotransmitter Function (W. S. Fields, ed.), pp. 1–15, S. Karger, Basel. Tarsy, D., Leopold, N., and Sax, D. S., 1974, Physostigmine in choreiform movement disorders, Neurology 24: 28–33.

    Google Scholar 

  • Tell, G. P., Schecter, P. J., Kock-Weser, J., Cantiniaux, P., Chabannes, J-P., and Lambert, P. A., 1981, Effects of gamma-vinyl GABA, N. Engl. J. Med. 305: 581–582.

    PubMed  CAS  Google Scholar 

  • Tolosa, E. S., and Lai, C., 1979, Meige disease: Striatal dopaminergic preponderance, Neurology 29: 1126–1130.

    PubMed  CAS  Google Scholar 

  • Uhr, S. B., Berger, P. A., Pruitt, B., and Stahl, S. M., 1984, R022–1319, a D-2 receptor antagonist for the treatment of Tourette syndrome, N. Engl. J. Med. 311: 989.

    PubMed  CAS  Google Scholar 

  • Uhr, S. B., Pruitt, B., Berger, P. A., and Stahl, S. M., 1985, Case report of four patients with Tourette syndrome treated with piquindone, a D-2 receptor antagonist, J. Clin. Psychophamacol. in press.

    Google Scholar 

  • Urquhart, J., Fara, J. W., and Willis, K. L., 1984, Rate-controlled delivery systems in drug and hormone research, Ann. Rev. Pharmacol. Toxicol. 24: 199–236.

    Article  CAS  Google Scholar 

  • Van Putten, T., 1975, The many faces of akathisia, Compr. Psychiatry 16: 43–47.

    Article  PubMed  Google Scholar 

  • Van Putten, T., May, P. R. A., and Marder, S. R., 1985, Akathisia with haloperidol and thiothixene, Arch. Gen. Psychiatry,in press.

    Google Scholar 

  • Van Woert, M. H., Rosenbaum, D., Howieson, J., and Bowers, M. B., 1977, Long-term therapy of myoclonus and other neurological disorders with L-5-hydroxytryptophan and carbidopa, N. Engl. J. Med. 296: 70–75.

    Article  PubMed  Google Scholar 

  • Victor, M., 1966, Treatment of alcoholic intoxication and the withdrawal syndrome. A critical analysis of the use of drugs and other forms of therapy, Psychosom. Med. 28 (4, part 2): 636–650.

    Google Scholar 

  • Villaneuve, A., Jus, K., and Jus, A., 1973, Polygraphic studies of tardive dyskinesia and of the rabbit syndrome during different stages of sleep, Biol. Psychiatry 6: 259–274.

    Google Scholar 

  • Washton, A. M., and Resnick, R. B., 1982, Outpatient opiate detoxification with clonidine, J. Clin. Psychiatry 436 (sec. 2): 39–41.

    Google Scholar 

  • Washton, A. M., Resnick, R. B., Perzel, J. F., and Garwood, J., 1981, Lofexidine, a clonidine analogue effective in opiate withdrawal, Lancet 1: 991–992.

    Article  Google Scholar 

  • Weiss, K. J., Ciranlo, D. A., and Shader, R. I., 1980, Physostigmine test in the rabbit syndrome and tardive dyskinesia, Am. J. Psychiatry 137: 627–628.

    PubMed  CAS  Google Scholar 

  • Weissberg, M. P., and Friedrich, E. V., 1978, Sydenham’s chorea: Case report of a diagnostic dilemma, Am. J. Psychiatry 135: 607–609.

    PubMed  CAS  Google Scholar 

  • Wells, C. E., and Duncan, G. W., 1980, Neurology for Psychiatrists, F. A. Davis, Philadelphia. Yahr, M. D. (ed.), 1973, The Treatment of Parkinsonism—The Role of DOPA Decarboxylase Inhibitors, Advances in Neurology Series, Vol. 2, Raven Press, New York.

    Google Scholar 

  • Young, R. R., and Delwaide, P. J., 1981, Drug therapy of spasticity, N. Engl. J. Med. 304: 28–33.

    Article  PubMed  CAS  Google Scholar 

  • Zilm, D. H., Sellers, E. M., and MacLeod, S. M., 1975, Propranolol effect on tremor in alcohol withdrawal, Ann. Intern. Med. 83: 234–236.

    PubMed  CAS  Google Scholar 

Download references

Author information

Author notes

  1. Stephen M. Stahl

    Present address: Neuroscience Research Centre, Merck Sharp and Dohme Research Laboratories, Terlings Park-Eastwick Road, Harlow, Essex, CM 20 2QR, UK

Authors and Affiliations

  1. VA-Stanford Mental Health Clinical Research Center, Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California, 94305, USA

    Stephen M. Stahl

  2. Laboratory of Neuropsychopharmacology, Schizophrenia Biologic Research Center, Veterans Administration Medical Center, Palo Alto, California, 94304, USA

    Stephen M. Stahl

Authors
  1. Stephen M. Stahl
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Ensor Foundation Research Laboratory, William S. Hall Psychiatric Institute, Columbia, South Carolina, USA

    Nandkumar S. Shah Ph.D. (Director, Research Professor) (Director, Research Professor)

  2. Department of Neuropsychiatry and Behavioral Science, University of South Carolina School of Medicine, Columbia, South Carolina, USA

    Nandkumar S. Shah Ph.D. (Director, Research Professor) & Alexander G. Donald M.D. (Director, Professor and Chairman) (Director, Research Professor) &  (Director, Professor and Chairman)

  3. William S. Hall Psychiatric Institute, Columbia, South Carolina, USA

    Alexander G. Donald M.D. (Director, Professor and Chairman) (Director, Professor and Chairman)

Rights and permissions

Reprints and permissions

Copyright information

© 1986 Plenum Publishing Corporation

About this chapter

Cite this chapter

Stahl, S.M. (1986). Introduction Neuropharmacology of Movement Disorders. In: Shah, N.S., Donald, A.G. (eds) Movement Disorders. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-5038-5_1

Download citation

  • DOI: https://doi.org/10.1007/978-1-4684-5038-5_1

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4684-5040-8

  • Online ISBN: 978-1-4684-5038-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation